Aquestive(US:AQST) Globenewswire·2026-03-14 10:50Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's New Drug Application for Anaphylm [4][6]. Company Overview - Aquestive Therapeutics, Inc. is under scrutiny for allegedly providing false and misleading information regarding the approval timeline for its New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film [6]. - The company claimed confidence in the NDA submission and optimistic expectations for approval by the FDA's Prescription Drug User Fee Act (PDUFA) date of January 31, 2026 [6]. Legal Proceedings - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that the company concealed material adverse facts about the NDA, particularly regarding human factors in the use of its sublingual film [6]. Stock Performance - Following the announcement of deficiencies identified by the FDA in the NDA on January 9, 2026, Aquestive's stock price fell by more than 37% on the same day [7].